The U.S. Preventive Services Task Force has added aromatase inhibitors to its list of medications recommended to reduce breast cancer risk in women at increased risk. This is a change from the group’s 2013 recommendation on using drugs to lower breast cancer risk. Of course, they are recommending the DRUGS.

Most people who have had or are experiencing the side-effects of tamoxifen-like medications may argue with the above recommendation, however, there are NATURAL inhibitors of aromatase as well as nutrients that tend to “pull-out” undesirable estrogens.

In the USPSTF’s final recommendation statement in JAMA, other recommendations are largely unchanged. Women aged 35 years and older who are at increased risk for breast cancer can be offered medications, also including tamoxifen and raloxifene, if they are at low risk for side effects (grade B recommendation).

We recommend our Breast Cancer Prevention BUNDLE which includes great aromatase inhibitors:

Breast Cancer Prevention Protocol Bundle conners clinic bundle 1024x1024@2x